share_log

CVRx, Inc. (NASDAQ:CVRX) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny

CVRx, Inc. (NASDAQ:CVRX) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny

CVRx公司(納斯達克股票代號:CVRX)股票暴跌27%,看似有機會,但需要再仔細覈查。
Simply Wall St ·  06/04 18:25

Unfortunately for some shareholders, the CVRx, Inc. (NASDAQ:CVRX) share price has dived 27% in the last thirty days, prolonging recent pain.    The drop over the last 30 days has capped off a tough year for shareholders, with the share price down 46% in that time.  

對於一些股東來說,不幸的是,CVRx, Inc.(納斯達克股票代碼:CVRX)的股價在過去三十天內下跌了27%,延續了最近的痛苦。過去30天的下跌結束了股東艱難的一年,股價在此期間下跌了46%。

Although its price has dipped substantially, you could still be forgiven for feeling indifferent about CVRx's P/S ratio of 3.4x, since the median price-to-sales (or "P/S") ratio for the Medical Equipment industry in the United States is also close to 3.2x.  Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.    

儘管其價格已大幅下跌,但您對CVRx的3.4倍市盈率漠不關心仍然是可以原諒的,因爲美國醫療設備行業的中位市銷率(或 “市盈率”)也接近3.2倍。但是,不加解釋地忽略市銷率是不明智的,因爲投資者可能會忽視一個明顯的機會或一個代價高昂的錯誤。

NasdaqGS:CVRX Price to Sales Ratio vs Industry June 4th 2024

納斯達克GS: CVRX 與行業的股價銷售比率 2024 年 6 月 4 日

How Has CVRx Performed Recently?

CVRx 最近的表現如何?

With revenue growth that's superior to most other companies of late, CVRx has been doing relatively well.   Perhaps the market is expecting this level of performance to taper off, keeping the P/S from soaring.  If the company manages to stay the course, then investors should be rewarded with a share price that matches its revenue figures.    

由於最近的收入增長優於大多數其他公司,CVRx的表現相對較好。也許市場預計這種表現水平將逐漸減弱,從而防止市銷率飆升。如果公司設法堅持下去,那麼投資者應該獲得與其收入數字相匹配的股價作爲獎勵。

Want the full picture on analyst estimates for the company? Then our free report on CVRx will help you uncover what's on the horizon.  

想全面了解分析師對公司的估計嗎?然後,我們關於CVRx的免費報告將幫助您發現即將發生的事情。

How Is CVRx's Revenue Growth Trending?  

cvRx 的收入增長趨勢如何?

CVRx's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.  

CvRx的市銷率對於一家預計只會實現適度增長且重要的是表現與行業持平的公司來說是典型的。

If we review the last year of revenue growth, the company posted a terrific increase of 60%.   Spectacularly, three year revenue growth has ballooned by several orders of magnitude, thanks in part to the last 12 months of revenue growth.  Therefore, it's fair to say the revenue growth recently has been superb for the company.  

如果我們回顧一下去年的收入增長,該公司公佈了60%的驚人增長。引人注目的是,三年的收入增長激增了幾個數量級,這在一定程度上要歸功於過去12個月的收入增長。因此,可以公平地說,該公司最近的收入增長非常好。

Shifting to the future, estimates from the six analysts covering the company suggest revenue should grow by 33% per annum over the next three years.  That's shaping up to be materially higher than the 11% each year growth forecast for the broader industry.

展望未來,報道該公司的六位分析師的估計表明,未來三年收入將每年增長33%。這將大大高於整個行業每年11%的增長預期。

In light of this, it's curious that CVRx's P/S sits in line with the majority of other companies.  It may be that most investors aren't convinced the company can achieve future growth expectations.  

有鑑於此,奇怪的是,CvRx的市銷率與其他大部分公司持平。可能是大多數投資者不相信公司能夠實現未來的增長預期。

What We Can Learn From CVRx's P/S?

我們可以從CvRx的市銷率中學到什麼?

CVRx's plummeting stock price has brought its P/S back to a similar region as the rest of the industry.      While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.

CvRx的股價暴跌使其市銷率回到了與該行業其他公司相似的區域。儘管市銷率不應該成爲決定你是否買入股票的決定性因素,但它是衡量收入預期的有力晴雨表。

Despite enticing revenue growth figures that outpace the industry, CVRx's P/S isn't quite what we'd expect.  There could be some risks that the market is pricing in, which is preventing the P/S ratio from matching the positive outlook.  However, if you agree with the analysts' forecasts, you may be able to pick up the stock at an attractive price.    

儘管誘人的收入增長數據超過了該行業,但CvRx的市銷率並不完全符合我們的預期。市場可能存在一些定價風險,這使市銷率無法與樂觀的前景相匹配。但是,如果你同意分析師的預測,你也許能夠以誘人的價格買入股票。

Having said that, be aware  CVRx is showing 3 warning signs in our investment analysis, you should know about.  

話雖如此,請注意,CVRx在我們的投資分析中顯示了3個警告信號,您應該知道。

If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

如果過去盈利增長穩健的公司處於困境,那麼你可能希望看到這些盈利增長強勁、市盈率低的其他公司的免費集合。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論